Login here to update your profile  
My Profile

Jiazhi Sun, M.D.


Assistant Professor

profile Image
Email: jsun@health.usf.edu
Phone: (813) 974-7468
Office: MDC, 3027A
Mailing address 12901 Bruce B. Downs Blvd. 3027A MDC30
Tampa, FL 33612
  • MS, West Virginia University, United States - 1994.
  • MBBS, Beijing Medical University, China - 1986.
    Interdisciplinary & Emerging Signature Programs
    Cancer Biology, Cardiovascular.
    Research Summary

    Dr. Jiazhi Sun has been trained in the field of basic medical science and molecular biology and received M.D. degree from Peking University in 1986. After completing his residency and fellowship training at Peking University in 1990 and graduate studies on targeting Q-binding protein into yeast mitochondria at West Virginia University in 1994, he received two-terms postdoc training at the University of Pittsburgh and H. Lee Moffitt Cancer Center in the field of Pharmacology, Biochemistry and Drug Discovery from 1994 to 2003. He currently holds joint Assistant Professor of Department of Pharmaceutical Sciences of College of Pharmacy and Department of Molecular Medicine of Morsani College of Medicine at University of South Florida. His research focuses on Ras and ER signaling study, HDL-Receptor RNA alternative processing, and K-Ras, GPCR, BH3 protein and VDR/ER drug discovery targeting by utilizing Target-Guided Synthesis (TGS) approach and conventional intervention. Dr. Sun has more than 15-year professional experience in academic field including Drug Discovery, Signal Transduction, Apoptosis, Cancer Biology and Cardiovascular field, also leading collaborative Institutional and Pharmaceutical Industry rational design/targeted-therapeutic approach and development of FTI, GGTI and Kinase inhibitors (tyrosine, serine/threonine and sphingosine) and nuclear hormone receptor mimics as well as BH3-mimics as drug candidates and “Chemical-Genetics” tool/model. Since 1994, he has been involved in multiple programs yielding two U.S. patents, more than 30 peer-reviewed papers, book chapter, numerous awards including AFLAC Scholar in Cancer Research Award sponsored by American Association of Cancer Research and more than 30 scientific professional presentations.


    Selected Publications
  • Kazi A, Sun J, Doi K, Sung SS, Takahashi Y, Yin H, Rodriguez JM, Becerril J, Berndt N, Hamilton AD, Wang HG, Sebti SM. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. The Journal of biological chemistry. 286(11) : 9382-92, 2011.
  • Wei J, Kitada S, Rega MF, Emdadi A, Yuan H, Cellitti J, Stebbins JL, Zhai D, Sun J, Yang L, Dahl R, Zhang Z, Wu B, Wang S, Reed TA, Wang HG, Lawrence N, Sebti S, Reed JC, Pellecchia M. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Molecular cancer therapeutics. 8(4) : 904-13, 2009.
  • Hu X, Sun J, Wang HG, Manetsch R. Bcl-XL-templated assembly of its own protein-protein interaction modulator from fragments decorated with thio acids and sulfonyl azides. Journal of the American Chemical Society. 130(42) : 13820-1, 2008.
  • Sun J, Wang DA, Jain RK, Carie A, Paquette S, Ennis E, Blaskovich MA, Baldini L, Coppola D, Hamilton AD, Sebti SM. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. 24(29) : 4701-9, 2005.
  • Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 24(20) : 3236-45, 2005.
  • Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer research. 64(10) : 3586-92, 2004.
  • Jiang K, Sun J, Cheng J, Djeu JY, Wei S, Sebti S. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis. Molecular and cellular biology. 24(12) : 5565-76, 2004.
  • Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M. Inhibition of angiogenesis by Abeta peptides. Angiogenesis. 7(1) : 75-85, 2004.
  • Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J, Sebti SM, Chellappan SP. Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. Molecular and cellular biology. 24(21) : 9527-41, 2004.
  • Sun J, Ohkanda J, Coppola D, Yin H, Kothare M, Busciglio B, Hamilton AD, Sebti SM. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer research. 63(24) : 8922-9, 2003.

  • Memberships
  • American Association of Colleges of Pharmacy (Member, 2012 - Present)
  • National Academy of Inventors (Member, 2012 - Present)
  • American Chemical Society (Member, 2004 - Present)
  • American Association for Cancer Research (Active member, 1995 - Present)
  • American Association for Advancement of Science (Member, 1991 - Present)

  • Awards/Honors
  • AFLAC Scholar in Cancer Research Award (AACR - 1999)

  • Patents & Licensing
  • US patent 20110130568-Acylsulfonamides and Processes (Hu X, Sun J, Wang H-G and Manetsch R - 2011)
  • Bcl-xl Protein Modulation (US patent 61/030,756) (Hu X, Sun J, Wang H-G and Manetsch R - 2010)
  • Target Guided Synthesis (US patent 61/030,753) (Hu X, Sun J, Wang H-G and Manetsch R - 2008)

  • Lectures
  • "Repositioning of the FDA-approved tyrosine kinase inhibitors targeting histone deacetylases, B-Raf and other proteins" NAI. FL, United States - 2012.
  • "Target-Guided Synthesis (TGS) of BH3-mimics and Potential Application on K-Ras Targeting" Drug Discovery in Post-genomic Era Symposium. FL, United States - 2012.
  • "Inhibition of Geranylgeranyltransferase I: A Novel Approach to Cancer Therapy" FASEB. AZ, United States - 2002.
  • "Geranylgeranyltransferase I (GGTase I) Inhibitors Induce Mammary Tumor Regression in Oncogenic H-Ras Transgenic Mice: Validation of GGTase I as a Cancer therapy Target" AACR. LA, United States - 2001.
  • "Farnesyltransferase Inhibitors in Lung Cancer Treatment: Important Translational Issues" International Lung Cancer Conference. CO, United States - 1999.
  • "GGTI-298 Blocks Human Tumor Growth in G0/G1 by a Mechanism Involving Induction of p21WAF1, Rb hypophosphorylation and Inhibition of Cyclin-dependent Kinases" AACR. LA, United States - 1998.

  • Profile last modified on 01/31/2013